KLK3 and prostate carcinoma: Radiation treatment of the primary in patients with oligometastatic disease recently became an additional option for patients, due to STAMPEDE-arm H. In line with the data suggesting the overall survival (OS) benefit with the addition of docetaxel to ADT in patients with metastatic hormone-naive prostate cancer (GETUG-15, STAMPEDE and CHAARTED trials) [11,12,18], Oudard et al. investigated the utility of this strategy in patients with rising PSA, who are hormone-naive at a high-risk of metastatic progression in a randomized trial.